HK-listed CStone Pharmaceuticals drops most in nearly 3 years

CStone Pharmaceuticals

28/12/2021 06:26

** Shares of CStone Pharmaceuticals  2616.HK  fall as much
as 13.6% to HK$7.30, biggest daily percentage drop since debut
in February 2019
    ** Stock, third biggest decliner in the Hang Seng Composite
Index  .HSCI , sinks to its lowest since May 2020; among the 30
biggest percentage decliners on the Hong Kong bourse 
    ** Biopharmaceutical products developer says its new drug
application for precision therapy AYVAKIT has been approved in
Hong Kong for treatment of metastatic gastrointestinal stromal
tumor harbouring a PDGFRA D842V mutation  urn:newsml:reuters.com:*:nFWN2TC0E3
    ** Shanghai-based firm says it has an exclusive
collaboration and license agreement with its partner, Blueprint
Medicines, for the development and commercialization of AYVAKIT
in Mainland China, Hong Kong, Macau and Taiwan
    ** Says Blueprint Medicines retains development and
commercial rights of AYVAKIT for the rest of the world
    ** Hong Kong's healthcare index  .HSCIH  down 1.4%
    ** Hang Seng Composite Index  .HSCI  slips 0.5% while Hang
Seng Index  .HSI  gains 0.1%
    ** Stock down 16.2% this year, as of last close


 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))